Immune study of azacitidine and venetoclax in first AML treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with acute myeloid leukemia (AML).
- You have not received any previous treatment for AML.
- You are about to start or are receiving a chemotherapy combination of azacitidine and venetoclax as your first treatment.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the body processes venetoclax when it's given with azacitidine as a first treatment for acute myeloid leukemia (AML). It aims to understand how well the drug works and how the body handles it.
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
This study looks at how leukemia cells become resistant to two common drug combinations: azacitidine plus venetoclax or azacitidine plus ivosidenib. It is for people with newly diagnosed AML who are about to start one of these treatments.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This study looks at how a person’s leukemia “disease state” changes over time for adults with acute myeloid leukemia (AML) who cannot receive the strongest (“intensive”) chemotherapy. It tests using oral venetoclax as a first treatment option, which may help control the disease for people ineligible for intensive chemo.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.